Pharmaceuticals

Polaryx Therapeutics

Polaryx Therapeutics released FY2026 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0538 (forecast USD -0.02)

Polaryx Therapeutics Receives FDA Fast Track Designation and Plans to Initiate Phase II Clinical Trials

Polaryx Therapeutics released FY2025 earnings on March 24 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1978 (forecast USD -0.19)

Polaryx Therapeutics released FY2024 Q4 earnings on March 24 (EST), actual revenue USD 0, actual EPS USD -0.0184

Polaryx Therapeutics released FY2025 Q4 earnings on March 24 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.034 (forecast USD -0.02)

Polaryx Therapeutics' PLX-200 Receives FDA Fast Track Designation

Polaryx Therapeutics released FY2024 9 Months Earnings on November 21, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.1827

Polaryx Therapeutics released FY2024 Q3 earnings on November 21 (EST), actual revenue USD 0, actual EPS USD -0.0202

Polaryx Therapeutics released FY2025 9 Months Earnings on November 21, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.1677

Polaryx Therapeutics released FY2025 Q3 earnings on November 21 (EST), actual revenue USD 0, actual EPS USD -0.0312

Polaryx Therapeutics released FY2025 Q2 earnings on September 19 (EST), actual revenue USD 0, actual EPS USD -0.0225

Polaryx Therapeutics released FY2025 semi-annual earnings on September 19 (EST), actual revenue USD 0, actual EPS USD -0.1361

Polaryx Therapeutics released FY2024 Semi-Annual Earnings on September 19 (EST), with actual revenue of USD 0 and EPS of USD -0.9711

Polaryx Therapeutics released FY2024 Q2 earnings on September 19 (EST), actual revenue USD 0, actual EPS USD -0.0358

Polaryx Therapeutics released FY2024 earnings on August 5, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.8875

Polaryx Therapeutics released FY2023 annual earnings on August 5, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.3535

Polaryx Therapeutics released FY2024 Q1 earnings on August 5, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.1266

Polaryx Therapeutics released FY2025 Q1 earnings on August 5, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.1139

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

MetaVia

Vida Global

BiomX

Micware

Tradr 2X Long XNDU Daily ETF

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

PLYX

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards | PLYX Stock News

StockTitan

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards | PLYX Stock News

XAIR

KALV

Short sellers have increased their positions in small-cap healthcare stocks, particularly those under $2 billion market cap, leading to heightened bearish sentiment. Sensei Biotherapeutics tops the list with a short interest of 63.85%, followed by KalVista Pharmaceuticals at 38.35%. Conversely, Beyond Air and Polaryx Therapeutics have minimal short interest at 0.50%. The healthcare sector has underperformed, with the Health Care Select Sector SPDR® Fund declining 6.23% year-to-date, despite the S&P 500's 5.62% rally.

businessinsider

Beyond Air

KalVista Pharma

Most and least shorted healthcare stocks with up to $2B market cap in May

Earnings Watch

Polaryx Therapeutics | 10-K: FY2025 Revenue: USD 0

Polaryx Therapeutics, Inc. (PLYX) received a Buy rating from Maxim Group, as reported by analyst Jason McCarthy. The company's shares closed at USD 5.27, with an analyst consensus of Moderate Buy and a price target of $10.00. McCarthy, who covers the Healthcare sector, has an average return of -14.2% and a 32.73% success rate on his stock recommendations.

Tip Ranks

Aprea Therapeutics

Moleculin Biotech

Plus Therapeutics

Polaryx Therapeutics, Inc. (PLYX) Receives a Buy from Maxim Group

Polaryx Therapeutics, Inc. (PLYX) shares rose 10% after the FDA granted Fast Track Designation for all four indications in its SOTERIA Phase 2 trial. This includes PLX-200 for rare lysosomal storage disorders: CLN2, CLN3, Krabbe disease, and Sandhoff disease. The trial aims to evaluate safety and efficacy, starting in late 2026. PLYX's stock closed at $5.70, down 6.86%, but pre-market trading saw it rise to $6.25.

nasdaq

Nasdaq

Polaryx Shares Rise As FDA Grants Fast-track Status Across All SOTERIA Trial Indications

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | PLYX Stock News

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | PLYX Stock News

Polaryx Therapeutics (NASDAQ:PLYX) shares rose 4.9% to $6.47, despite a significant drop in trading volume. Maxim Group initiated coverage with a "buy" rating and a target price of $10.00. Currently, the stock holds an average "buy" rating among analysts, with a target price of $10.00. The company focuses on developing therapies for rare pediatric lysosomal storage disorders.

Market Beat

Polaryx Therapeutics (NASDAQ:PLYX) Trading 4.9% Higher   - Time to Buy?

Polaryx Therapeutics(PLYX.US)

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards | PLYX Stock News

Most and least shorted healthcare stocks with up to $2B market cap in May

Polaryx Therapeutics | 10-K: FY2025 Revenue: USD 0

Polaryx Therapeutics, Inc. (PLYX) Receives a Buy from Maxim Group

Polaryx Shares Rise As FDA Grants Fast-track Status Across All SOTERIA Trial Indications

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | PLYX Stock News

Polaryx Therapeutics (NASDAQ:PLYX) Trading 4.9% Higher - Time to Buy?